Microneedle ocular patch: fabrication, characterization, and ex-vivo evaluation using pilocarpine as model drug

References

• Patel A, Cholkar K, Agrahari V, et al. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47–64.
   PubMedGoogle Scholar
• Molokhia SA, Thomas SC, Garff KJ, et al. Anterior eye segment drug delivery systems: current treatments and future challenges. J Ocul Pharmacol Ther. 2013;29(2):92–105.
   PubMed Web of Science ®Google Scholar
• Gaudana R, Ananthula HK, Parenky A, et al. Ocular drug delivery. Aaps J. 2010;12(3):348–360.
   PubMed Web of Science ®Google Scholar
• Dubald M, Bourgeois S, Andrieu V, et al. Ophthalmic drug delivery systems for antibiotherapy—a review. Pharmaceutics. 2018;10(1):10.
   Web of Science ®Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131–1135.
   PubMed Web of Science ®Google Scholar
• Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26(4):207–218.
   PubMed Web of Science ®Google Scholar
• Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6(6):735–754.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Pavesio C, Ohno S, et al. Intraocular inflammation. New York (NY): Springer; 2016.
   Google Scholar
• Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye. 1998;12(2):234–236.
   PubMedGoogle Scholar
• Kim YC, Chiang B, Wu X, et al. Ocular delivery of macromolecules. J Control Release. 2014;190:172–181.
   PubMed Web of Science ®Google Scholar
• Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci. 2004;45(7):2342–2347.
   PubMed Web of Science ®Google Scholar
• Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs . Eur J Pharm Biopharm. 2007;66(3):303–317.
   PubMed Web of Science ®Google Scholar
• Bin Sahadan MY, Tong WY, Tan WN, et al. Phomopsidione nanoparticles coated contact lenses reduce microbial keratitis causing pathogens. Exp Eye Res. 2019;178:10–14.
   PubMed Web of Science ®Google Scholar
• Morrison PWJ, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Ther Deliv. 2014;5(12):1297–1315.
   PubMedGoogle Scholar
• Garg T, Malik B, Rath G, et al. European Journal of Pharmaceutical Sciences Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 2014;53:10–16.
   PubMed Web of Science ®Google Scholar
• Foureaux G, Franca JR, Nogueira JC, et al. Ocular inserts for sustained release of the angiotensin-converting enzyme 2 activator, diminazene aceturate, to treat glaucoma in rats. PLoS One. 2015;10(7):e0133149.
   PubMed Web of Science ®Google Scholar
• Attama AA, Reginald-Opara JN, Uronnachi EM, et al. Nanomedicines for the eye: current status and future development. In: Hamblin MR, Avci P, Prow TW, editors. Nanoscience in dermatology. Amsterdam, Netherlands: Elsevier; 2016. p. 323–336.
   Google Scholar
• Zhang Y, Chen Y, Yu X, et al. A flexible device for ocular iontophoretic drug delivery. Biomicrofluidics. 2016;10(1):011911.
   PubMed Web of Science ®Google Scholar
• Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug delivery. J Ocul Pharmacol Ther. 2016;32(2):67–82.
   PubMed Web of Science ®Google Scholar
• Lee SS, Hughes P, Ross AD, et al. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27(10):2043–2053.
   PubMed Web of Science ®Google Scholar
• Jiang J, Gill HS, Ghate D, et al. Coated microneedles for drug delivery to the eye. Invest Ophthalmol Vis Sci. 2007;48(9):4038–4043.
   PubMed Web of Science ®Google Scholar
• Khandan O, Famili A, Kahook MY, et al. Titanium-based, fenestrated, in-plane microneedles for passive ocular drug delivery. Paper presented at the 34th Annual International Conference of the IEEE Engineering in Medicine and Biology Society EMBC; 2012 August 29; San Diego, CA.
   Google Scholar
• Thakur RRS, Tekko IA, Al-Shammari F, et al. Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery. Drug Deliv Transl Res. 2016;6(6):800–815.
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Saju A, Cheerla KD, et al. Corneal delivery of besifloxacin using rapidly dissolving polymeric microneedles. Drug Deliv and Transl Res. 2018;8(3):473–483.
   PubMed Web of Science ®Google Scholar
• Than A, Liu C, Chang H, et al. Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery. Nat Commun. 2018;9(1):4433.
   PubMedGoogle Scholar
• Patel SR, Lin ASP, Edelhauser HF, et al. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res. 2011;28(1):166–176.
   PubMed Web of Science ®Google Scholar
• Kim YC, Oh KH, Edelhauser HF, et al. Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles. Eur J Pharm Biopharm. 2015;95(B):398–406.
   PubMedGoogle Scholar
• Song HB, Lee KJ, Seo IH, et al. Impact insertion of transfer-molded microneedle for localized and minimally invasive ocular drug delivery. J Contr Rel. 2015;209:272–279.
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Group GLS. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% tid in patients with open-angle glaucoma or ocular hypertension, Graefe’s. Arch Clin Exp Ophthalmol. 2000;238(5):433–439.
   PubMed Web of Science ®Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007;24(12):1007–1016.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082.
   PubMed Web of Science ®Google Scholar
• Stegmann RC, Grieshaber MC, Grieshaber HR, inventors; Grieshaber Ophthalmic Research Foundation, assignee. Method and device for the treatment of glaucoma. US8951221B2. 2015 Feb 10.
   Google Scholar
• Natarajan JV, Chattopadhyay S, Ang M, et al. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. PLoS One. 2011;6(9):e24513.
   PubMed Web of Science ®Google Scholar
• Üstündağ-Okur N, Gökçe EH, Bozbıyık Dİ, et al. Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis. Expert Opin Drug Deliv. 2015;12(11):1791–1807.
   PubMed Web of Science ®Google Scholar
• Wang F, Chen L, Zhang D, et al. Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study. J Drug Target. 2014;22(9):849–858.
   PubMed Web of Science ®Google Scholar
• Varshochian R, Riazi‐Esfahani M, Jeddi-Tehrani M, et al. Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. J Biomed Mater Res A. 2015;103(10):3148–3156.
   PubMed Web of Science ®Google Scholar
• Schmitz WL, inventor; Arnis Inc., assignee. Auto-retracting needle injector system. US5167641A. 1992 Dec 1.
   Google Scholar
• Tu H, Smedley GT, Haffner DS, et al, inventors; Glaukos Corp., assignee. Ocular implant delivery systems. US9987472B2. 2018 June 5.
   Google Scholar
• Mehta P, Al-Kinani AA, Haj-Ahmad R, et al. Electrically atomised formulations of timolol maleate for direct and on-demand ocular lens coatings. Eur J Pharm Biopharm. 2017;119:170–184.
   PubMed Web of Science ®Google Scholar
• Thrimawithana TR, Young S, Bunt CR, et al. Drug delivery to the posterior segment of the eye. Drug Discov Today. 2011;16(5–6):270–277.
   PubMed Web of Science ®Google Scholar
• Davis BM, Normando EM, Guo L, et al. Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes. Small. 2014;10(8):1575–1584.
   PubMed Web of Science ®Google Scholar
• Hutton-Smith LA, Gaffney EA, Byrne HM, et al. Ocular pharmacokinetics of therapeutic antibodies given by intravitreal injection: estimation of retinal permeabilities using a 3-compartment semi-mechanistic model. Mol Pharm. 2017;14(8):2690–2696.
   PubMedGoogle Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–1203.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossovertrial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge× 6 mm needle versus a 29 gauge× 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26(10):1663–1678.
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Dave K, Venuganti VVK. Microneedles in the clinic. J Contr Rel. 2017;260:164–182.
   PubMed Web of Science ®Google Scholar
• Young G. Ocular sagittal height and soft contact lens fit. J Br Contact Lens Assoc. 1992;15(1):45–49.
   Google Scholar
• Garner LF. Sagittal height of the anterior eye and contact lens fitting. Am J Optom Physiol Opt. 1982;59(4):301–305.
   PubMedGoogle Scholar
• Park J-H, Allen MG, Prausnitz MR. Polymer microneedles for controlled-release drug delivery. Pharm Res. 2006;23(5):1008–1019.
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177–1185.
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Sharir M, Nardin GF, et al. Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. Am J Ophthalmol. 1992;114(1):1–7.
   PubMed Web of Science ®Google Scholar